The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Infectious complications as a key driver of non-relapse mortality with bispecific antibodies
In this video, Muhammad Bilal Abid, MD, Texas Tech University Health Sciences Center, Lubbock, TX, discusses findings from a study evaluating non-relapse mortality (NRM) in patients receiving bispecific antibodies, highlighting the importance of considering NRM as a cumulative measure of toxicities. The analysis highlights that infectious complications contribute to NRM as much as, or more than, cytokine release syndrome (CRS), neurotoxicity, and other adverse events combined. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
